Specialists from Novosibirsk State Pedagogical University, in collaboration with industrial partners, have developed a new class of four-component metabiotics—drugs designed to restore the balance of the human microbiome. This was reported by the university’s press service. The results are published in the journal “Scientific Notes of V.I. Vernadsky Crimean Federal University. Biology. Chemistry”.
Metabiotics are the purified lysates of probiotic bacteria, containing short-chain fatty acids (SCFAs like acetic, propionic, and butyric), bacteriocins, antioxidant enzymes, and cell membrane components. Unlike probiotics, which introduce live bacteria into the gut, metabiotics focus on creating an environment that supports and enhances the activity of beneficial bacteria already present.
The drugs help to reduce the level of pathogenic microflora, are involved in the regulation of immune processes, including innate and acquired immunity, and can control the expression of entry receptors for SARS‐CoV‐2. The components of metabiotics are also involved in neutralizing free radicals and binding metal ions that participate in oxidative reactions.
The development is based on ten years of research into the mechanisms of interaction between humans and their microbiome. The products are designed to correct microflora disorders related to nutrition, medication, stress, and environmental factors.
Earlier it was reported that the US Food and Drug Administration (FDA) was initiating action to remove concentrated ingestible fluoride prescription drug products for children from the market. The agency cited concerns over the potential negative effects of fluoride on the intestinal microbiome, as well as possible links to thyroid disorders, obesity, and lower IQ.
